Clinical Trials

    Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

    Investigator: Jun Zhang

    Study Coordinator: Gabrielle Hayes

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT04675333

    Phone: 734.415.918

    Protocol Number: PRO00035973

    Description


    This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of evorpacept (ALX148) + pembrolizumab + 5FU + platinum and of pembrolizumab + 5FU + platinum in patients with metastatic or unresectable, recurrent HNSCC who have not yet been treated for their advanced disease. The study comprises of an initial safety lead-in followed by a randomized portion.